• MiMedx Group Inc MDXG.OQ reported quarterly adjusted earnings of 15 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of 5 cents. The mean expectation of six analysts for the quarter was for earnings of 7 cents per share. Wall Street expected results to range from 6 cents to 8 cents per share.

• Revenue rose 22.4% to $113.73 million from a year ago; analysts expected $106.78 million.

• MiMedx Group Inc's reported EPS for the quarter was 11 cents​.

• The company reported quarterly net income of $15.19 million.

• MiMedx Group Inc shares had fallen by 21.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 17.6% in the last three months.​

• In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for MiMedx Group Inc is $10.00, about 46.5% above its last closing price of $5.35

This summary was machine generated from LSEG data February 25 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)